Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial
Karim Fizazi(Université de Lille), Stéphane Culine(Hôpital Saint-Louis), Mathilde Cancel(Centre Hospitalier Universitaire de Tours), Brigitte Laguerre(Centre Eugène Marquis), Frédéric Rolland(Institut de Cancérologie de l'Ouest), J. Mardiak(National Institute of Cardiovascular Diseases), Mária Rečková(National Institute of Cardiovascular Diseases), Gwénaëlle Gravis(Centre National de la Recherche Scientifique), Guilhem Roubaud(Institut Bergonié), Natacha Naoun(Université Paris-Saclay), Béata Juzyna(UniCancer Group), Lionnel Geoffrois(Institut de Cancérologie de Lorraine), Lance C. Pagliaro(The University of Texas MD Anderson Cancer Center), Christine Chevreau(Institut Claudius Regaud), Christine Théodore(Hôpital Foch), Jean-Christophe Eymard(Institut Jean Godinot), C. Logothetis(The University of Texas MD Anderson Cancer Center), Aude Fléchon(Institut Català d'Ornitologia), R. Delva, Gwénaël Le Teuff(Université Paris-Saclay)
Cited by 18
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k